UroGen Pharma Ltd. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
UroGen Pharma Ltd. (URGN) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $5.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-05
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $1.73M, a 94.29% decline year-over-year.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $4.15M, a 89.75% decline year-over-year.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $28.27M, a 59.59% decline year-over-year.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $40.21M, a 231.19% increase year-over-year.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $139.25M, a 29.29% increase from fiscal 2024.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $107.70M, a 119.48% increase from fiscal 2023.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $49.07M, a 23.71% decline from fiscal 2022.
- UroGen Pharma Ltd. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $64.32M, a 18.55% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.88M 10-Q · filed 2026-08-05 | $34.15M derived: sum of 3 quarters · filed 2026-08-05 | $74.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.15M 10-Q · filed 2026-05-06 | $32.42M derived: sum of 2 quarters · filed 2026-05-06 | $72.63M derived: sum of 3 quarters · filed 2026-05-06 | $102.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $68.48M derived: sum of 2 quarters · filed 2026-03-02 | $98.81M derived: sum of 3 quarters · filed 2026-08-05 | $139.25M 10-K · filed 2026-03-02 |
| 2025-09-30 | $40.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $70.54M derived: sum of 2 quarters · filed 2026-08-05 | $110.97M 10-Q · filed 2025-11-06 | $180.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $30.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $70.77M 10-Q · filed 2026-08-05 | $140.73M derived: sum of 3 quarters · filed 2026-08-05 | $152.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $40.43M 10-Q · filed 2026-05-06 | $110.40M derived: sum of 2 quarters · filed 2026-05-06 | $122.54M derived: sum of 3 quarters · filed 2026-05-06 | $134.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $69.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $82.11M derived: sum of 2 quarters · filed 2026-03-02 | $94.19M derived: sum of 3 quarters · filed 2026-03-02 | $107.70M 10-K · filed 2026-03-02 |
| 2024-09-30 | $12.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $24.22M derived: sum of 2 quarters · filed 2025-11-06 | $37.74M 10-Q · filed 2025-11-06 | $41.27M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.60M 10-Q · filed 2025-08-07 | $29.14M derived: sum of 3 quarters · filed 2025-08-07 | $40.47M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $13.52M 10-Q · filed 2025-05-12 | $17.05M derived: sum of 2 quarters · filed 2025-05-12 | $28.39M derived: sum of 3 quarters · filed 2025-05-12 | $32.12M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $14.87M derived: sum of 2 quarters · filed 2025-03-10 | $18.60M derived: sum of 3 quarters · filed 2025-03-10 | $49.07M 10-K · filed 2025-03-10 |
| 2023-09-30 | $11.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $15.07M derived: sum of 2 quarters · filed 2024-11-06 | $45.54M 10-Q · filed 2024-11-06 | $68.66M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $34.20M 10-Q · filed 2024-08-13 | $57.33M derived: sum of 3 quarters · filed 2024-08-13 | $84.99M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $30.47M 10-Q · filed 2024-05-13 | $53.59M derived: sum of 2 quarters · filed 2024-05-13 | $81.26M derived: sum of 3 quarters · filed 2024-05-13 | $81.17M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $23.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $50.79M derived: sum of 2 quarters · filed 2024-03-14 | $50.70M derived: sum of 3 quarters · filed 2024-03-14 | $64.32M 10-K · filed 2024-03-14 |
| 2022-09-30 | $27.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $27.58M derived: sum of 2 quarters · filed 2023-11-14 | $41.20M 10-Q · filed 2023-11-14 | $50.83M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $13.53M 10-Q · filed 2023-08-10 | $23.16M derived: sum of 3 quarters · filed 2023-08-10 | $41.49M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.62M 10-Q · filed 2023-05-11 | $23.25M derived: sum of 2 quarters · filed 2023-05-11 | $41.58M derived: sum of 3 quarters · filed 2023-05-11 | $52.57M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $27.96M derived: sum of 2 quarters · filed 2023-03-24 | $38.95M derived: sum of 3 quarters · filed 2023-03-24 | $54.26M 10-K · filed 2023-03-24 |
| 2021-09-30 | $18.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $29.31M derived: sum of 2 quarters · filed 2022-11-10 | $44.63M 10-Q · filed 2022-11-10 | $94.26M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $10.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $26.30M 10-Q · filed 2022-08-11 | $75.93M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $15.31M 10-Q · filed 2022-05-10 | $64.95M derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $49.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $124.14M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $74.50M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |